A live archive of receipt-bound excerpts from company earnings calls. No generated thesis, no recommendation — just the recorded language, its source coordinates, and a direct path into the ticker dossier or live Terminal.来自公司财报电话会的可追溯摘录档案。没有生成式投资结论，也没有推荐——只有原始表述、来源坐标，以及进入个股档案或实时终端的直接入口。
Start free in Terminal免费开始使用终端649 verified call records份已核验电话会记录 · 7788 exact facts条精确事实 · 2026-10-26 → 2026-11-01
Browse the full archive page by page. Search on this page by ticker, period, category, or speaker; every card preview is a verbatim call excerpt.分页浏览完整档案。在本页按代码、期间、分类或发言人搜索；每张卡片预览均为电话会原文摘录。
Showing records 2305–2400 of 6702.显示第 2305–2400 条，共 6702 条。
“I wanted to ask you, given the product ramp and improving demand environment, should we expect the first quarter fiscal to represent the low point for both sequential revenue growth and incremental margins with acceleration as we move throughout the year, with regard to FY 2027?”
“We are maintaining the guidance we provided in May and expect revenue to be between $2.188 billion and $2.303 billion, and adjusted EBITDA to be between $432 million and $447 million, with adjusted EPS between $0.89 and $0.92.”
“It's really about our focus on protecting gross profit dollars and the impact of that is, as you correctly calculated, the midpoint of the range, that would imply 300 basis points-400 basis points in margin compression in the September quarter.”
“As such, our 2026 revenues guidance range is updated to $475 million-$495 million, and the adjusted operating income guidance range is updated to $55 million-$65 million for this segment, which is roughly 60% higher when compared to the midpoint to the 2025 results.”
“Adjusted revenue was $919 million, exceeding our guidance range and increasing 9.5% sequentially, driven by strong volume growth of 7% and an increase in Average Selling Prices of 2%.”
“We expect segment profit margins to contract by approximately 450-500 basis points compared to 2025, primarily due to the New York City renewal contract, including service pricing adjustments from the competitive procurement process and the inclusion of minority and women-owned subcontractor requirements by the City of New York.”
“Given the strength of our order trends and backlog, we are confident we can deliver organic revenue growth for 2026 above the target in our three-year model.”
“If you look at a trailing 12-month revenue being up 10%, high 38% margin fee income is up 16%, as Mike referenced, and that fee income continues to be an important part of our growth story.”
“The change in cash during the second quarter of 2026 as compared to the first quarter of 2026, was driven by the net loss in the second quarter of 2026, excluding the impact of non-cash charges such as stock-based compensation and amortization of our intangible and right of use assets, as well as timing of cash received from customers for revenue and related payments of rebates to payers, and the timing of cash paid to third parties for services related to operating expenses and inventory production.”
“We expect to nominate additional development candidates in 2027, further accelerating the expansion of our pipeline.”
“Full year operating margin for Viavi was 20.6%, up 630 basis points from fiscal year 2025, and was a result of higher fall-through driven by higher revenue and favorable product mix.”
“This Q2 production grew at very healthy WAC, low LTV, it continues the trend of good borrower demand for our product, even during what's been an unstable year-to-date so far, 2026 economic market.”
“On a full-year 2026 basis, we expect approximately $10 million of incremental operating expenses and a gross margin impact of roughly 75 basis points associated with these growth initiatives.”
“As we've shared with you since first releasing our fiscal 2026 guidance last November, based on our normal seasonality as well as the timing of our growth investments this year, we expected Q4 to have an outsized impact on the year.”
“More specifically, Anthony, the range relative to kind of the change from our original guidance in that $30 million-$40 million top line and probably about $4 million-$5 million pressure on margins just from having a little bit lower top line and some of that operational infrastructure.”
“Turning to guidance, we continue to expect JELMYTO net product revenue of $97 million to $101 million for 2026, which represents growth of roughly 3%-7% over 2025.”
“Gross bookings were 22% year-over-year to more than $58 billion, above the high end of our guidance and marking our fourth consecutive quarter above 20% growth.”
“Adjusted EBITDA rose in the second quarter, driven by higher volumes and better margin, with adjusted EBITDA margin expanding to 16.5% from 12.2% in the first quarter.”
“With the continued strong demand in both artificial intelligence and defense, we also remain confident in our ability to achieve 15%-20% organic revenue growth for 2027 and 2028, as previously shared.”
“Direct lending volumes declined by approximately half sequentially and compared to the second quarter of 2025, while private equity deal activity also slowed materially.”
“We anticipate sustaining our growth trajectory with steadily improving profitability, targeting a 10% adjusted EBITDA margin by 2028.”
“For the full year of 2026, we now expect total revenue in the range of $1.584 billion-$1.601 billion.”
“Net leverage was 1.18 times at quarter end, consistent with our target range, total platform liquidity increased to $939 million, driven in large part by the close of our SBIC fund.”
“We continue to see 2026 adjusted EBITDA margins of approximately 40%, and we expect free cash flow of approximately $2.1 billion.”
“Based on our outlook and assessment of the current market, we continue to anticipate double-digit revenue growth and strong earnings in 2026, with even higher earnings expected in 2027, by which time many of our newer large projects in our backlog should be in the construction phase.”
“Moving to the chart on the right, we show an illustrative portfolio margin mix beyond 2030 that reflects the impact of an additional approximately 2 GW of long-term contracts as we continue to execute on the Talen flywheel.”
“The company posted operating expenses of $7.8 million in the second quarter of 2026, reflecting our scaled investment in sales and marketing, which we expect to be approximately $2 million for the full year 2026.”
“Because we expect these elevated promotions to create a revenue headwind of approximately $7 million in the second half, we are updating our revenue and EBITDA margin expectations for the balance of the year.”
“For the third quarter, we expect revenues to be between $460 million and $473 million, gross profit to be between $148 million and $152 million, ex-TAC gross profit to be $184 million-$190 million, adjusted EBITDA to range from $51.5 million-$56.5 million, and non-GAAP net income to be $38 million-$42 million.”
“Demand remains exceptionally strong, as reflected in a record backlog and the long-term agreement, which increased to a record of $650 million at the end of June 30, 2026.”
“Our year-over-year revenue growth rate at 5% helped us generate $57.7 million in adjusted EBITDA, or an adjusted EBITDA margin of 18.7%.”
“These operational results translated into record free cash flow generation during the quarter and support an increase to our full-year 2026 production guidance.”
“For the fourth quarter of fiscal 2026, we expect revenue between $760 million and $780 million, and adjusted EBITDA between $100 million and $105 million.”
“At Great Basin, we further strengthened the commercial foundation of the 2028 expansion project, bringing contracted demand to approximately one Bcf per day and revising the project design to reflect a 48 in pipeline, resulting in both increased capital investment and annual margin estimates for the project.”
“We did that with a New York Harbor 2-1-1 crack margin, net of the renewable volume obligation, or RVO, more than CAD 10 per barrel lower than in the second quarter of 2022.”
“The business saw continued success in paid acquisition with gross profit from paid traffic acquisition up 37% year-over-year.”
“Turning to our outlook, as Mike mentioned, consistent with our previous direction of model towards the lower end of the $1.2 billion-$1.4 billion range, we are narrowing our 2026 total net product revenue guidance to $1.2 billion-$1.3 billion.”
“Finally, I'm pleased to reaffirm our fiscal 2026 and 2027 adjusted EPS guidance ranges, as well as our long-term adjusted EPS growth target of 5%-7%.”
“While acquisitions have temporarily impacted our gross margin, we continue to explore and harvest synergies and expect to see our gross margin exceeding 70% in the future, similar to when we went public.”
“Q2 organic growth on a normalized basis was approximately 4% when taking into consideration approximately 630 basis points of ERP advanced orders, partially offset by approximately 100 basis points of our SKU rationalization plan headwinds and the partial separation timing benefit shared in Q1, mostly impacting the MedSurg business.”
“Gross profit increased 68% sequentially to a record $560,000, while gross margins improved to 73.6%.”
“As a result, we expect to recognize a benefit of approximately $247.1 million as a reduction of cost of sales with a corresponding receivable in the third quarter of 2026.”
“Professional services revenue was $9 million, up 100%, reflecting increased hardware refresh installations as well as higher access control volume, which drive growth in professional services ARPU.”
“NuScale reported revenue of $0.1 million for the three months ended June 30th, 2026, compared to $8.1 million in the same period last year.”
“At quarter end, SSLP had $55 million of undrawn capacity, and we expect to continue to grow this portfolio opportunistically as conditions in the cash flow market warrant.”
“We expect near-term adjusted gross margin in the 25%-26% range as the actions we have taken to mitigate material cost pressures are beginning to take hold, and we expect those benefits to build as we move through the second quarter.”
“Those include Healthcare Solutions within Professional Lines, power and renewables within Energy Solutions, political risk and political violence within Syndicate 1969, and a strong pipeline of Platform Partner syndicates to drive fee-based income growth.”
“We have raised the low end of our Same Center NOI growth guidance to 2.75% from 2.25% previously, with the high end remaining unchanged at 4.25%.”
“In addition, for the combined SiTime business, including TPD, we expect gross margin to be approximately 68% ±1 point, operating expenses in the range of $80 million-$85 million as we continue to invest in growth, interest income of approximately $4 million, and a share count of approximately 32.8 million shares, which includes approximately 3.6 million shares issued in conjunction with the TPD acquisition.”
“Finally, our Q2 free cash flow margin was just over 18%, exceeding our outlook.”
“You hinted that those were under review before, can you just help us understand maybe how you were thinking about that outlook, particularly like the prior goals for at least 50 basis points of restaurant margin expansion and that low teens unit growth?”
“Earlier today, Sight Sciences released financial results for the second quarter ended June 30, 2026, and raised its revenue guidance and lowered its adjusted operating expense guidance for full year 2026.”
“Our sports margin hit a record 17% for the quarter, reflecting improved pricing and risk management, the continued growth of parlays and most importantly, the quality and durability of our customer base.”
“Revenue grew 20% year-over-year to $346 million, once again, with no significant pull forward of revenue and non-GAAP gross margin expanded for the sixth consecutive quarter.”
“As a reminder, increasing the percentage of revenue from hosted contracts will have a temporary negative impact on revenue, with every 1% increase in hosted revenue resulting in a $2 million-$3 million reduction in reported revenue, depending on renewal quarter and contract length.”
“Distribution revenue increased 2%, with subscriber churn continuing to moderate, consistent with trends the largest distributors have reported publicly, and the benefit of partner station buy-ins we have executed.”
“With our operating leverage, growing recurring revenue, and expanding defense pipeline, we expect 2026 to be a major step towards sustained profitability, crossing into positive free cash flow in 2027 as Merlin enters operational service.”
“CS pricing increased 8% sequentially and 21% year-over-year, while sales volumes improved 19% from the first quarter.”
“Excluding revenue related to Alcon, our second quarter product sales were $27.2 million, down 19% compared to the prior-year period, reflecting heightened competitive trialing as well as broader marketplace headwinds.”
“With our earlier stage pipeline, we expect to identify the recommended phase II dose for RMC-5127 in the second half of this year, share initial clinical data in 2027.”
“As a reminder, we have been waiting for build schedules tied to our initial ePOD orders to firm and had expected the majority of these sales to impact 2027, with some spillover into 2028, and potential for a modest amount of revenue to be recorded this year.”
“Based on this, we would expect to generate an internal rate of return in the teens, consistent with our development stage target range, and peak annual royalties of approximately $110 million-$190 million based on AstraZeneca's peak sales expectations.”
“Given the recent acquisition of Stellus, some of the near-term focus will be around deleveraging, which, coupled with natural growth in cash earnings in the back half of the year, should bring our leverage ratio back in line with our longer-term target in the mid 2x EBITDA by the end of this year versus approximately 2.8x at the end of the Q2 pro forma for Stellus.”
“Revenue increased 2% year-over-year to $389 million, and Policies in Force increased 6% year-over-year, ending the quarter at 484,000 policies.”
“In line with our long-term strategic plan for our residential business, continues to become a larger part of our overall portfolio and represented 83% of our total revenue in the quarter, with segment EBITDA margin improving 340 basis points sequentially to 19%.”
“Customer support and operations expense was $26.2 million, and as a percentage of revenue was 5.3%, improving 68 basis points year-over-year and continuing a multi-year trend of steady operating leverage.”
“We recognized GAAP revenue for the second quarter of $41 million and now expect full year 2026 GAAP revenue of $65 million-$75 million.”
“We now expect full year revenue in the range of $3.4 billion-$3.5 billion, representing approximately 37%-38% growth year-over-year.”
“Is this lower margin outlook more of a function of weaker than expected sales leverage or commodity pressure?”
“How do you think about this debate of whatever mid-cycle and whatever Phillips 66 on free cash flow potential might be going forward, what's the right dividend strategy for Phillips as you fulfill, for example, your midstream growth and so on?”
“As a result of our acquisition volume so far this year and our visibility into a large pipeline of opportunities, we are increasing our acquisitions guidance to $150 million-$160 million.”
“We also believe the increased share buyback program of $30 million is another key mechanism to drive shareholder value going forward.”
“We continue to expect that the aggregate impact on our full-year 2026 pre-tax adjusted operating income will be approximately $525 million-$575 million.”
“Our demand indicators remain positive, and we expect to deliver 14% adjusted EBITDA growth year-over-year at the midpoint.”
“Adjusted EBITDA increased 5% to $385 million, with margin expansion driven by improving productivity, stronger operating leverage, and continued progress in direct delivery.”
“Growth in our energy segment backlog was primarily driven by natural gas power generation, which accounted for approximately $1.4 billion of the sequential increase during the quarter.”
“As such, we're maintaining our full year outlook for core and all-in net sales, margin, and earnings per share metrics.”
“TinySwitch-5 now has designs in production and should contribute meaningful revenue in the second half of 2026, particularly at appliance customers where we've had a number of recent wins.”
“International Omnipod revenue grew over 35% on a reported basis and 33% on a constant currency basis, driven primarily by volume and continued favorable price mix realization.”
“At the midpoint of our guidance implies approximately 27% year-over-year adjusted net income growth and even stronger EPS growth, more than doubling 2024 adjusted net income in just two years while continuing to generate an adjusted ROE above 20%.”
“With the increase in Patient Affordability revenues driving continued margin expansion and operating leverage, we expect gross profit margins between 62% and 63%, an increase compared to our prior guidance of 60%-62%.”
“Margin capture was 118%, including the benefit of refined product inventory draws during the April outage, partially offset by a $3 million FIFO headwind from declining crude oil prices.”
“Our adjusted EBITDAR margin expanded by 150 basis points year-over-year from 10.2% to 11.7% as our revenue growth outpaced our expense growth due to same-store occupancy improvement, favorable patient mix, and disciplined cost management.”
“Instrument revenue in the second quarter was $12.8 million, a decrease of 9% from $14.2 million in the second quarter of 2025, primarily reflecting a lower average selling price driven by customer mix, including lower-priced strategic Revio placements to key accounts and fewer Vega system shipments as academic and government funding constraints continued to pressure capital purchases.”
“Before moving on, given our robust revenue performance and strong outlook for this year, I'd like to mention some important growth investments we have accelerated into 2026 to support our ambitious revenue targets for this year and beyond.”
“We exceeded our revenue guidance, expanded gross margin sequentially, advanced our decentralized diagnostics pipeline in rapid tests and sample management solutions, and continued to position the business for sustainable growth and long-term shareholder value in the second half of 2026 and beyond.”
“Our full year 2026 guidance continues to be underpinned by our expectations for mid-single digit originations growth, a 1%-2% decline in average daily principal balance, and substantially flat operating expenses compared with the prior year.”
“At the midpoint of revised full year EBITDA guidance of $117 million-$120 million, the bridge is as follows: lower pass-through revenue, which consists of revenue on subcontractor and non-labor direct costs, are generally at far lower margins than labor-based service revenue.”
“On the back of these strong results, we are raising our 2026 guidance ranges for revenue and GAAP operating income by $300 million and $250 million respectively.”
“With strong first half performance and the impact of the Texas legislation, we expect to achieve adjusted earnings within the upper half of these ranges, or $310 million-$314 million and $4.89-$4.95.”
“We delivered 5% pro forma constant currency net sales growth over prior year and saw encouraging trends across several areas of the portfolio, including double-digit growth in global limb reconstruction and spine fixation, sequential momentum in biologics, and the restoration of Medicare reimbursement for bone growth stimulators, which removes a meaningful headwind for our therapeutic solutions business as we enter the second half of the year.”
“Reflecting stronger gross margin and lower operating expenses, Orion's Q1 2027 net income was $2 million, or $0.47 per diluted share, or $0.48 basic per common share.”
“Sponsors continue to face a difficult exit environment amid a wide bid-ask spread between sellers and buyers, geopolitical uncertainty, a less predictable macroeconomic outlook, and the possibility of slower growth alongside persistent inflation.”
“Turning to our financial results in the quarter, we delivered total revenue of $2.8 billion and adjusted EBITDA of $660 million, for an adjusted EBITDA margin of 24%.”
“With our enterprise value approaching $90 billion and a robust pipeline of external growth opportunities, the access to additional capital enhances our ability to immediately finance our investment pipeline while remaining patient and opportunistic in accessing longer term and permanent capital.”
“Overall, in the first half of 2026, we almost doubled our international revenue versus the first half of 2025, driven by our focused commercial approach in target geographies.”
Try a ticker, period, category, or a call speaker.请尝试代码、期间、分类或电话会发言人。
This is a transcript-only, historically incomplete publication. Releases, filings, slides, consensus and price reaction are visibly marked as not joined; lower-evidence packets remain held instead of being inferred.这是仅基于电话会文本且历史覆盖尚不完整的发布。新闻稿、披露文件、演示材料、一致预期和股价反应均明确标注为未接入；证据不足的数据包会被暂缓，而非由推断补齐。